Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

---- ---- REVENUES $464,291 $464,291 -------- -------- COSTS AND EXPENSES: Research and development 14,022,930 10,550,371 General and administrative 4,069,370 2,619,745 --------- --------- Total costs and expenses 18,092,300 13,170,116 ---------- ---------- OPERATING LOSS (17,628,009) (12,705,825) INVESTMENT INCOME 109,524 896,402 INTEREST EXPENSE (756,912) (363,176) -------- -------- LOSS BEFORE INCOME TAXES (18,275,397) (12,172,599) PROVISION FOR INCOME TAXES - - --- --- NET LOSS $(18,275,397) $(12,172,599) ============ ============ COMPREHENSIVE NET LOSS: NET LOSS $(18,275,397) $(12,172,599) UNREALIZED GAIN (LOSS) ON AVAILABLE-FOR-SALE INVESTMENTS 1,089 - ----- --- COMPREHENSIVE NET LOSS $(18,274,308) $(12,172,599) ============ ============ NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER SHARE: BASIC $(0.78) $(0.57) DILUTED $(0.78) $(0.57) WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC 23,369,487 21,263,668 DILUTED 23,369,487 21,263,668
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ROOK, N.Y., Nov. 5 BioSp...pharmaceutical company developing first-in-class c...ancial results for the third quarter ended Septemb... in September of this year, the FDA,s Arthritis Ad...e of 12-0, the approval of XIAFLEX(TM) for the tre...
(Date:11/5/2009)... WORTH, Texas, Nov. 5 Wo...ed today that it has entered into a Letter of Inte...rtual Health Technologies, Inc. (OTC Bulletin Boar...,000,000 in cash and debt, 4,000,000 shares of WND...y WNDM on the Veriscrip technology being acquired ...
(Date:11/5/2009)...ONT, Calif., Nov. 5 Wafe...a leading developer of state-of-the-art genetic an...ears, Ph.D. has joined the company,s Scientific Ad...gning and commercializing novel molecular diagnost...nd on the development of computational biology sys...
(Date:11/5/2009)...PLYMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-Fir... ) ("BMP Sunstone" or the "Company") today announc... 2009 financial results on,Monday, November 9, 200... will hold a conference call at 5:00 pm ET on Nove.... Listeners may access the call by,dialing 1-888-...
Breaking Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4BMP Sunstone to Report Third Quarter 2009 Financial Results 2
...nical evidence continues to build for the company,...ma Sciences, Inc.,(OTC Bulletin Board: DSCI), a co...nounced that eleven clinical posters focusing on i... presented at next week,s,Clinical Symposium on Ad...ucts featured include MEDIHONEY dressing with Acti...
...HESDA, Md., Oct. 22 Micromet, Inc.,(Nasdaq: MITI...proprietary,antibodies for the treatment of cancer...unced that it will host a conference call and audi...m Eastern Time (3:00 pm,Central European Time) to ...Micromet anticipates releasing its financial resul...
...TON DOWN, England, Oct 22 Enigma Diagnostics,Limi... diagnostics company,announced today that it has s...stems., The licence provides Enigma with access t...methods for monitoring nucleic acid amplification,...ed Biosystems has granted,to the method claims of ...
Other Biology Technology:Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference 2Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference 3Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference 4Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 3Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 4Enigma Diagnostics Announces Patent Licence With Applied Biosystems 2
(Date:11/6/2009)...6 Auburn Hills, MI-based Law Enfor...talling its locker system and patent-pending Biome...Department of Health and Human Services, National ... The locker system will support the NIH,s entire p... nation,s medical research agency. The project is...
(Date:11/5/2009)...ity has been awarded a training grant in the amoun... under its Integrative Graduation Education and Re... IGERT grant to be awarded to Kent State. The gran... Reinvestment Act of 2009, runs through 2014. , ...nvironment aquatic resource sensing (EARS). The pu...
(Date:11/4/2009)...ember 4, 2009 Childhood obesity in the United Sta...an one fourth of advertising on daytime and prime ... continuing questions about the role television pl...ssue of the Journal of Nutrition Education and Be...ldren might be a large contributor to the problem....
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 1Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 2Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 3Senate Bill to Protect Patients Healthcare by Amending Medicare Coverage 48578 1Senate Bill to Protect Patients Healthcare by Amending Medicare Coverage 48578 2Senate Bill to Protect Patients Healthcare by Amending Medicare Coverage 48578 3Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 1Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 2Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 3Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 4
...us maculates, a fairly abundant species of grouper...of microscopic monogenean worms. This diversity of...abar grouper, Epinephilus malabaricus, another the...iversity prevails in all coral-reef fish, tens of ...m waiting to be discovered., , In the same way as...
... "biotechnology" elicits a range of emotions, from...en from the University of California in Riverside ...ublic knowledge of biotech, popular misperceptions... How is coexistence dealt with in the US and Europ...g companies or also the society at large" In the p...
...ger marsupial thylacine by being better built anat...ted with killing large prey, say Australian scient...and efficient bite and having larger energy needs ...ting relatively small prey while the dingo,s stron...ge prey as well. , Earlier studies had given ambi...
Other Biology News:Coral reef fish harbor an unexpectedly high biodiversity of parasites 2Coral reef fish harbor an unexpectedly high biodiversity of parasites 3How the public perceives biotech 2Tassie tiger no match for dingo 2
Polypropylene Plate Cover with stacking ridge from ABgene
Polypropylene Plate Cover from ABgene
...e components including positive and negative contr...tion in cultured cells and tissue sections. The in...ter sensitivity than biotinylated or digoxigenylat...try. The kit works well with GFP transfected cells...
SYBRGreen I nucleic acid gel stain from Sigma-Aldrich
Biology Products: